Tamsulosin in urology: beyond benign prostatic hyperplasia

G. G. Laxman Prabhu, Hiren Prajapati, Alok Chaturvedi, Nilanj Dave, Amit B. Jain

Research output: Contribution to journalReview article

Abstract

Tamsulosin, a third-generation uroselective α 1A adrenergic receptor blocker (antagonist), has been approved for the treatment of signs and symptoms of benign prostatic hyperplasia for more than two decades. Apart from this approved use, more recent evidence has been published regarding the off-label use of tamsulosin in various other urological conditions. However, further research is needed regarding the use of tamsulosin in these indications. This review highlights the possible therapeutic uses of tamsulosin for the management of various urological conditions.

Original languageEnglish
Pages (from-to)181-184
Number of pages4
JournalDrugs and Therapy Perspectives
Volume35
Issue number4
DOIs
Publication statusPublished - 10-04-2019

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Laxman Prabhu, G. G., Prajapati, H., Chaturvedi, A., Dave, N., & Jain, A. B. (2019). Tamsulosin in urology: beyond benign prostatic hyperplasia. Drugs and Therapy Perspectives, 35(4), 181-184. https://doi.org/10.1007/s40267-019-00611-1